Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05349201 · ClinicalTrials.gov registry record
CAR T Cells Real World Evidence Study Based on the French Hospital Claims Data Source (PMSI)
A clinical trial, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- 273
- Enrollment target
NCT05349201: Completed study, sponsored by Novartis Pharmaceuticals.
NCT05349201 is a clinical trial that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 273 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05349201 has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- 273 participants
- Enrollment target
Study Summary
This was a Retrospective cohort study based on the PMSI data source
Primary Outcome
Overall survival indicator was defined as all cause death recorded at the hospital (MSO, HAD, SSR). Patients were censored at the date of last hospitalization observed (MSO/HAD/SSR/ACE).
Interventions
- OTHER KYMRIAH
- OTHER YESCARTA
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 273 participants |
| Start Date | 2020-12-09 |
| Est. Completion | 2021-05-28 |
What the finished NCT05349201 record still lists
NCT05349201 is an observational study that tracks outcomes without assigning an intervention. The registered 273 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 2 interventions - of which KYMRIAH is the first listed.
NCT05349201 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05349201 about?
NCT05349201 is a clinical study titled "CAR T Cells Real World Evidence Study Based on the French Hospital Claims Data Source (PMSI)". This was a Retrospective cohort study based on the PMSI data source
What is the current status of trial NCT05349201?
This trial is currently completed. The enrollment target is 273 participants. The study started on 2020-12-09. Estimated completion is 2021-05-28.
What interventions are being tested in trial NCT05349201?
The interventions under investigation include: KYMRIAH (OTHER), YESCARTA (OTHER).
Who is sponsoring clinical trial NCT05349201?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07229430 · 273 participants · NA
Safety and Effectiveness Evaluation of the High-intensity Focused Ultrasound Device for Lifting Lax Submental and Neck Tissue
- NCT03808922 · 274 participants · Phase 3
Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study
- NCT04573504 · 274 participants · Phase 4
Antibiotics for Severe Perineal Laceration to Prevent Infection Following Repair
- NCT05289557 · 274 participants · Phase 3
The Efficacy and Safety of Bonjesta® for Nausea and Vomiting of Pregnancy in Pregnant Adolescents
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI